Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679601 | 0.92 | MAPT (0.82) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL13679575 | 0.90 | MAPT (0.73) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL5822958 | 0.89 | MAPT (0.72) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL13679552 | 0.89 | MAPT (0.69) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL14642440 | 0.89 | MAPT (0.71) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL13679715 | 0.89 | MAPT (0.69) | MAPTMEN1KMT2ALMNARAB9A | |
| SCHEMBL14615282 | 0.88 | MAPT (0.68) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL12831265 | 0.88 | MAPT (0.73) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL13679580 | 0.87 | MAPT (0.67) | MAPTMEN1KMT2AHTTKDM4E | |
| SCHEMBL15424127 | 0.87 | MAPT (0.68) | MAPTMEN1KMT2AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000023-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8772275-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2440544-B1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2364185-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2443104-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010147917-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010142426-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-12-16 | — | — | WO | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2227456-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | Siena Biotech S.p.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010062507-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010056588-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056620-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009134574-A2 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009074300-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | MAPT 3122/4885MEN1 2224/4885KMT2A 590/4885 |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | MAPT 3104/4885MEN1 3442/4885KMT2A 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.